Calderasib is a KRAS G12C inhibitor, a class of targeted therapies designed to address specific oncogenic mutations. This page compares Calderasib with other agents, including Adagrasib (Krazati), Docetaxel (Taxotere), and Pembrolizumab (Keytruda). While all agents target certain cancer types, their approved indications and mechanisms of action may differ.
Calderasib Alternatives: How It Compares to Other KRAS G12C Inhibitors
Hipa.ai Research · Source: ClinicalTrials.gov / AACT · Last updated: AI-augmented data · 0/5 curated
Source: ClinicalTrials.gov via AACT · Hipa.ai, 2026-05-07Download chart as PNG
The competitive landscape features established treatments such as Docetaxel (Taxotere), approved in 1996, and Pembrolizumab (Keytruda), approved in 2014. Calderasib is not yet approved, while pipeline drug Divarasib remains in Phase 3, approximately 1-2 years behind current approved options.
Quick comparison table
| Drug | Class | Approved indications | Dosing | Year approved | Lead pivotal endpoint | Annual cost (rough) |
|---|---|---|---|---|---|---|
| Calderasib | KRAS G12C inhibitor | — | Oral, once daily | Pipeline | — | — |
| Docetaxel (Taxotere) | Microtubule inhibitor | Breast cancer, Non-small cell lung cancer, Prostate cancer, +2 more | 75 mg/m2 intravenously every 3 weeks | 1999 | — | $3k |
| Pembrolizumab (Keytruda) | PD-1 inhibitor | melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, +3 more | 200 mg every 3 weeks or 400 mg every 6 weeks intravenously | 2015 | Overall Survival: 0.6Hazard Ratio @ 5 years | $191k |
| Adagrasib (Krazati) | KRAS G12C inhibitor | Non-small cell lung cancer, Colorectal cancer | 600 mg orally twice daily | 2022 | 43% | $237k |
| Divarasib | KRAS G12C inhibitor | — | 400 mg orally once daily | Pipeline | — | — |
Cost estimates are list-price approximations and do not reflect rebates, formulary tier, or out-of-pocket costs after benefits. The class-typical lead-pivotal endpoint here is Objective Response Rate (ORR); cells render each drug's actual pivotal endpoint, which may differ. The "Year approved" column shows the FDA approval year for non-small cell lung cancer specifically — drugs approved for other indications first appear with their this-indication date, or as Pipeline if not yet approved for this indication. Cross-trial comparisons can mislead — head-to-head Phase-3 data (when present) is below.
Calderasib vs Adagrasib (Krazati)
No head-to-head Phase-3 trial directly compares Calderasib with Adagrasib.
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Calderasib vs Docetaxel (Taxotere)
No head-to-head Phase-3 trial directly compares Calderasib with Docetaxel.
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Calderasib vs Pembrolizumab (Keytruda)
The pivotal head-to-head evidence comes from a head-to-head Phase-3 trial (NCT07190248) enrolling 675 participants, primary completion 2029-12.
Primary-endpoint values for NCT07190248 are not yet posted in the AACT results database.
Source: ClinicalTrials.gov via AACT — pulled directly from the trial's posted results. View the full trial record.
Pipeline alternatives
Investigational IL-17 / IL-17-related drugs in active Phase 3 development include Divarasib, sponsored by Hoffmann-La Roche. This agent is currently being evaluated in a lead Phase 3 trial, NCT03178552.
Choosing between Calderasib and its alternatives
Calderasib, as a KRAS G12C inhibitor, represents a targeted therapeutic option for patients with specific mutations. This mechanism of action offers a distinct approach compared to broader treatments like chemotherapy or immunotherapy. For example, Adagrasib (Krazati), another KRAS G12C inhibitor, has demonstrated an objective response rate (ORR) of 43%. When considering targeted therapies, factors such as the specific efficacy profile, safety considerations, and the convenience of oral administration, exemplified by Adagrasib’s 600 mg twice-daily dosing, can influence treatment selection.
Conversely, alternative treatment modalities may be considered for patients without a KRAS G12C mutation, or in situations where a different mechanism of action is preferred. Docetaxel (Taxotere), a microtubule inhibitor, provides a chemotherapy option, typically administered intravenously at 75 mg/m2 every 3 weeks. For an immunotherapy approach, Pembrolizumab (Keytruda), a PD-1 inhibitor, has shown an Overall Survival Hazard Ratio of 0.6 at 5 years, with dosing options of 200 mg every 3 weeks or 400 mg every 6 weeks intravenously. These established agents offer different efficacy and safety profiles, which may be more suitable depending on individual patient characteristics, disease stage, and prior treatment history.
This information is for educational purposes only and does not constitute medical advice; clinical decisions should always be made by a qualified prescriber.
Sources and methodology
Trial data was pulled from the ClinicalTrials.gov registry via the AACT relational mirror maintained by the Clinical Trials Transformation Initiative. AACT data freshness: .
Head-to-head trials cited on this page:
- NCT07190248: Calderasib vs Pembrolizumab · A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-…
Cross-trial comparison limitations:drugs without a direct head-to-head trial are compared using each drug's own pivotal trial. These trials enrolled different patient populations at different time points and used different statistical analysis sets. Cross-trial response-rate differences should not be interpreted as proof that one drug is more effective than another.
Related drug pages on Hipa.ai
Not medical advice. This page summarizes publicly-reported clinical trial data for informational purposes. Treatment decisions belong with a qualified prescribing clinician who knows your medical history. Drug approvals, dosing, and safety profiles change over time — always confirm with the current FDA prescribing information.
calderasibcalderasib alternativesalternativescomparisonnon-small cell lung cancercalderasib-kras-g12c-nsclccalderasib vs adagrasibcalderasib vs docetaxelcalderasib vs pembrolizumabcalderasib vs divarasib